No abstract available.
Diagnosis* ; Humans ; Liver Neoplasms* ; Liver Transplantation* ; Liver* ; Neoplasm Metastasis*

No abstract available.
Diagnosis* ; Humans ; Liver Neoplasms* ; Liver Transplantation* ; Liver* ; Neoplasm Metastasis*

Lymphoma is a kind of malignant tumors that takes place in the lymphoid and hematological system. It is important to establish appropriate and stable animal models of lymphoma and they are useful for the experimental research of mechanisms and efficient treatment of disease. In this article the establishment methods, characteristics and practical use of various animal models of lymphoma were reviewed.
Animals ; Disease Models, Animal ; Lymphoma ; Mice ; Mice, Nude ; Neoplasm Transplantation

Camptothecin/*pharmacology ; Liver Neoplasms, Experimental/*immunology ; Neoplasm Transplantation ; Sarcoma, Experimental/*immunology ; Transplantation, Isogeneic

Hematopoietic Stem Cell Transplantation ; Humans ; Multiple Myeloma ; pathology ; therapy ; Neoplasm Staging ; Transplantation, Autologous

Animals ; Camptothecin ; pharmacology ; Liver Neoplasms, Experimental ; immunology ; Mice ; Neoplasm Transplantation ; Sarcoma, Experimental ; immunology ; Transplantation, Isogeneic

Objective: To investigate the clinical significance of minimal residual disease (MRD) monitoring by using WT1 gene and flow cytometry (FCM) in patients with myelodysplastic syndrome (MDS) who receiving allogeneic stem cell transplantation (allo-HSCT). Methods: WT1 gene and MDS-related abnormal immunophenotype were examined by real-time quantitative polymerase chain reaction (RQ-PCR) and FCM, respectively. The bone marrow samples were collected from patients with MDS who received allo-HSCT from Feb, 2011 to Oct, 2015 in Peking University People's Hospital before and after transplantation. Results: Among 92 MDS patients, 40 (48.2%) patients were positive for WT1 (WT1(+)) and 9 (10.8%) patients were positive for flow cytometry (FCM(+)). 27 patients (29.3%) met the criteria of our combinative standard, MRDco (MRDco(+)). Only FCM(+) post-transplant (P<0.001) and MRDco(+) (P=0.017) were associated with relapse. The cumulative incidence of relapse (CIR) at 2 years were 66.7% and 1.2% (P<0.001) in FCM(+) and FCM(-) groups. MRDco(+) group had a 2-year CIR of 23.0% while MRDco(-) group had a 2-year CIR of 1.6% (P=0.004). The specificity of post-transplant WT1, FCM and MRDco to predict relapse was 59.0%, 96.4% and 74.7%, respectively. The sensitivity of these three MRD parameters to predict relapse was 66.7%. Conclusion: Post-transplant FCM and MRDco are useful tools to monitor MRD for MDS after transplantation. The preemptive intervention based on MRDco is able to reduce the relapse rate.
Flow Cytometry ; Hematopoietic Stem Cell Transplantation ; Humans ; Myelodysplastic Syndromes/therapy* ; Neoplasm Recurrence, Local ; Neoplasm, Residual ; Stem Cell Transplantation ; Transplantation, Homologous ; WT1 Proteins

OBJECTIVETo establish an subcutaneous xenotransplanted tumor model of human ameloblastoma in nude mice.

METHODSAmeloblastoma cells were absorbed by primary culture, repeat attachment and pancreas proteolytic enzyme were both used to purify them. Then, the purified cells were implanted subcutaneously into the nude mice. The specimens were respectively investigated by microscope in different spots after implanting.

RESULTSAmeloblastoma cells can survive in all of the 8 nude mice. The xenograft can be found on 23 days after implanting. The rate of successful inocutation is 25%. The subcutaneously xenotransplanted tumor cells can be found with microscope in the inter-muscle tissues of nude mice.

CONCLUSIONThe subcutaneously xenotransplanted tumor model of human ameloblastoma in nude mice was successfully established and it may benefit to further studies on this tumor.

An 81-year-old woman with a raised pigmented nodule over her left cornea for 7 months duration was examined. Dark conjunctival pigmentation was observed in the upper bulbar fornix conjunctiva. She had previously undergone primary surgical excision of a malignant conjunctival melanoma four years earlier. The tumor separated easily from the corneal surface, but remained slightly attached to the corneoscleral surface. A corneoscleral lamellar dissection of 3 mm in width and 2 mm in depth as well as a corneoscleral lamellar keratoplasty for the reconstruction of the corneoscleral defect were performed. The wide upper bulbar and fornix conjunctiva were excised, and an amniotic membrane transplantation was performed. Biopsy revealed an invasive melanoma with a depth of 1 mm. Left, right, and inferior tumor margins of the corneoscleral lesion and the pigmentary lesion in the conjunctiva were free of the tumor. After surgery, 0.04% mitomycin was administered topically 4 times daily for 4 weeks. There was no recurrence 2 years after surgery, and systemic evaluation revealed no metastasis.
Aged, 80 and over ; Amnion/*transplantation ; Conjunctival Neoplasms/*surgery ; *Corneal Transplantation ; Female ; Humans ; Melanoma/*surgery ; Neoplasm Recurrence, Local ; Recurrence

OBJECTIVETo compare the outcomes of adult patients with acute lymphoblastic leukemia (ALL) who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) and allogeneic hematopoietic stem cell transplantation (allo-HSCT).

METHODSFrom Jan 2007 to Dec 2010, 106 adult ALL patients were retrospectively divided into two groups, 50 in auto-HSCT group and 56 in allo-HSCT group. Auto-HSCT group included 21 patients with high-risk, 46 patients in CR1 and 4 cases in CR2. All the 50 patients had negative minimal residual disease (MRD) prior to HSCT. Allo-HSCT group included 44 patients with high risk, 51 patients in CR1 and 5 cases in CR2, 15 patients with positive MRD before allo-HSCT. response, regulatory T cells (Treg), cytokines levels and treatment-related adverse effects were observed.

RESULTSOf the total 106 patients, 29 patients relapsed at a medium follow-up of 22.9(0.8-63.3) months. The 3-year cumulative relapse rate (RR) was (29.9±8.0) % in auto-HSCT group and (32.7±6.8) % in allo-HSCT group. There were no significant differences in RR and overall survival (OS) between auto-HSCT and allo-HSCT groups, even of stratified risk groups. In standard risk group, 3-year OS was (77.1±13.2) % in auto-HSCT group and (90.9±8.7) % in allo-HSCT group (P=0.739). In high-risk group, 3-year OS was (68.7±10.8) % after auto-HSCT and (45.2±8.5) % after allo-HSCT (P=0.094).

CONCLUSIONDue to acceptable RR and OS, adult ALL patients with no MRD before HSCT showed favorable survival. Auto-HSCT may be a considerable choice for adult ALL patients with negative MRD when lacking of donors for allo-HSCT.